- Home
- SNFCA vs AARD Comparison
SNFCA vs AARD Comparison
Compare SNFCA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNFCA
- AARD
- Stock Information
- Founded
- SNFCA 1965
- AARD 2017
- Country
- SNFCA United States
- AARD United States
- Employees
- SNFCA N/A
- AARD N/A
- Industry
- SNFCA Finance: Consumer Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- SNFCA Finance
- AARD Health Care
- Exchange
- SNFCA Nasdaq
- AARD Nasdaq
- Market Cap
- SNFCA 234.1M
- AARD 231.9M
- IPO Year
- SNFCA N/A
- AARD 2025
- Fundamental
- Price
- SNFCA $8.01
- AARD $10.18
- Analyst Decision
- SNFCA
- AARD Strong Buy
- Analyst Count
- SNFCA 0
- AARD 8
- Target Price
- SNFCA N/A
- AARD $30.75
- AVG Volume (30 Days)
- SNFCA 25.0K
- AARD 174.5K
- Earning Date
- SNFCA 11-14-2025
- AARD 11-13-2025
- Dividend Yield
- SNFCA N/A
- AARD N/A
- EPS Growth
- SNFCA 2.26
- AARD N/A
- EPS
- SNFCA 0.89
- AARD N/A
- Revenue
- SNFCA $339,824,006.00
- AARD N/A
- Revenue This Year
- SNFCA N/A
- AARD N/A
- Revenue Next Year
- SNFCA N/A
- AARD N/A
- P/E Ratio
- SNFCA $9.05
- AARD N/A
- Revenue Growth
- SNFCA 5.49
- AARD N/A
- 52 Week Low
- SNFCA $7.32
- AARD $4.88
- 52 Week High
- SNFCA $12.94
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- SNFCA 42.55
- AARD 39.22
- Support Level
- SNFCA $7.90
- AARD $9.70
- Resistance Level
- SNFCA $8.20
- AARD $10.94
- Average True Range (ATR)
- SNFCA 0.23
- AARD 0.84
- MACD
- SNFCA 0.01
- AARD -0.23
- Stochastic Oscillator
- SNFCA 20.63
- AARD 29.76
About SNFCA Security National Financial Corporation
Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.